AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1526682
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 1 g daily i.v. for one week (Control)
Trial: 29672831
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg retigabine
Trial: 26969416
Drug: Rosuvastatin 5
RxNorm normalized name: rosuvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5 to 40 mg
Trial: 26969416
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 to 40 mg
Trial: 26969416
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 and 40 mg
Trial: 24207098
Drug: Intra-arterial clot
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial clot retrieval with the Solitaire FR device after intravenous tissue plasminogen activator
Trial: 18724539
Drug: gemcitabine (Gemzar)
RxNorm normalized name: gemcitabine Injection [Gemzar]
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine (Gemzar) plus 3 mg/kg of infliximab (Remicade)
Trial: 18724539
Drug: gemcitabine (Gemzar)
RxNorm normalized name: gemcitabine Injection [Gemzar]
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine (Gemzar) plus 5 mg/kg of infliximab (Remicade)
Trial: 16521701
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) 1,800 mg/d with vitamin E 300 mg/d and vitamin C 600 mg/d
Trial: 16521701
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (vitamin E 300 mg/d and vitamin C 600 mg/d without EPA)
Trial: 654296
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of biguanide treatment
Trial: 30621974
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + ticagrelor
Trial: 30621974
Drug: Registry cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Registry cohort (Aspirin + clopidogrel)
Trial: 26324329
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg/day add-on to dapagliflozin plus metformin
Trial: 26324329
Drug: Placebo add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo add-on to dapagliflozin plus metformin
Trial: 24929184
Drug: Low flavanol
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flavanol apple puree (25 mg epicatechin)
Trial: 24929184
Drug: High flavanol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavanol apple puree (100 mg epicatechin)
Trial: 20828648
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 mg)
Trial: 23033226
Drug: Pharmacist-led warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led warfarin self-management program
Trial: 17641565
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (minimum of four needles, electroacupuncture preferred, strong electrical stimulation to needles placed in muscle, course of at least 10 treatments)
Trial: 15882556
Drug: Caffeine 300
RxNorm normalized name: caffeine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 300 mg/day
Trial: 12522677
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy with carboplatin plus ACNU (arm A)
Trial: 12522677
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy with cisplatin plus BCNU (arm B)
Trial: 7664215
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 to 100 mg once daily
Trial: 7664215
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg once daily + 12.5 mg HCTZ
Trial: 2693078
Drug: X‐Prep (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: X‐Prep (a Senna preparation) combined with an enema
Trial: 354042
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily doses of acebutolol
Trial: 354042
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acebutolol with chlorexolone
Trial: 18353666
Drug: DHB 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHB 1.25 mg i.v.
Trial: 12095953
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet intervention (n=58); weekly cooking course for 1 year, trained by professional chefs in the use of natural ingredients.
Trial: 6657201
Drug: Ascorbate or
RxNorm normalized name: Sodium Ascorbate Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascorbate or citrate (orthomolecular therapy)
Trial: 16213057
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release tablets containing felodipine under fed conditions
Trial: 16213057
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release tablets containing felodipine under fasting conditions
Trial: 16213057
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release tablets containing felodipine
Trial: 9952138
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravenous ondansetron (prophylaxis)
Trial: 9952138
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment with 1 mg intravenous ondansetron (if necessary)
Trial: 7573905
Drug: Pentazocine 0.40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 0.40 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group P/M)
Trial: 7573905
Drug: Ketamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.25 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group K25/M)
Trial: 7573905
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group K50/M)
Trial: 6961763
Drug: Labetalol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (mean daily dose 636 mg)
Trial: 6961763
Drug: Propranolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (mean dose 276 mg)
Trial: 27612922
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide (4 mg), PRN regimen
Trial: 27612922
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (Ozurdex), single injection
Trial: 23800946
Drug: l-menthol
RxNorm normalized name: L-menthol
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: l-menthol
Trial: 23042771
Drug: Low-dose thoracic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose thoracic computed tomography (performed in the first and sixth years)
Trial: 21693030
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg/day from cycle day 1 to 9
Trial: 21693030
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 100 mg/day from cycle day 3 to 7
Trial: 24884651
Drug: Increased therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased therapy time (from 8.6 to at least 13 hours a week) with interventions focused on strength, mobility, and balance.
Trial: 24884651
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy according to the Dutch stroke Guideline.
Trial: 23311172
Drug: Compound granule
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound granule prescription of thunberg fritillary bulb
Trial: 12461391
Drug: OP‐1 Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OP‐1 Implant
Trial: 22544644
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 100 mg (40 μCi) [¹⁴C]‐lacosamide over 60 min
Trial: 22544644
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 100 mg (40 μCi) [¹⁴C]‐lacosamide as an oral solution
Trial: 20378999
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (half-dose trandolapril plus half-dose valsartan)
Trial: 17977544
Drug: No danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No danazol treatment (Control)
Trial: 11773543
Drug: Heliox therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heliox therapy (70% helium and 30% oxygen)
Trial: 11511328
Drug: Heliox therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heliox therapy
Trial: 9696169
Drug: Ketorolac (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (10 mg every 4 to 6 h as needed, up to four daily doses)
Trial: 9696169
Drug: Acetaminophen-codeine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen-codeine (600 mg-60 mg every 4 to 6 h as needed, up to six daily doses)
Trial: 47538
Drug: Leucocyte-poor blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte-poor blood (L.P.B.)
Trial: 31345462
Drug: Adjunctive sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive sertraline (400 mg/day for 2 weeks, then 200 mg/day for 12 weeks, tapered over 3 weeks)
Trial: 31345462
Drug: Placebo (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (standard therapy with 7-14 days of intravenous amphotericin B and oral fluconazole)
Trial: 31345462
Drug: Adjunctive sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive sertraline
Trial: 28906040
Drug: lokivetmab (1–3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lokivetmab (1–3.3 mg/kg, monthly injectable)
Trial: 28906040
Drug: ciclosporin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciclosporin (5 mg/kg/once daily)
Trial: 22734234
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (10 mg/d) and bicyclol (25 mg, tid.)
Trial: 22734234
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (10 mg/d)
Trial: 17115982
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 to 200 mg daily)
Trial: 15095933
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel (Plavix) combination therapy
Trial: 15095933
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and warfarin combination therapy
Trial: 9502626
Drug: Streptokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase and subcutaneous heparin treatment
Trial: 2656331
Drug: PSK immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSK immunotherapy (n = 21)
Trial: 27657997
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (200 mg daily for 12 weeks)
Trial: 24143092
Drug: Advanced medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced medications
Trial: 16261567
Drug: Guanfacine (noradrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (noradrenergic agonist)
Trial: 2401176
Drug: Radical operation
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical operation plus chemotherapy
Trial: 2401176
Drug: Radical operation
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical operation plus chemotherapy in Stage II and III lesions
Trial: 6772449
Drug: Topical slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical slow-release nitroglycerin
Trial: 6772449
Drug: Oral slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral slow-release nitroglycerin
Trial: 6364030
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg I.V. indomethacin just after diagnosis
Trial: 6364030
Drug: I.V. or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. or oral indomethacin (ad libitum) after 48 hours
Trial: 31430578
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (EST)
Trial: 16041631
Drug: Lidocaine 4%
RxNorm normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 4% cream (LMX4)
Trial: 7576976
Drug: [131I]MIBG treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [131I]MIBG treatment alone
Trial: 2179782
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin 5000 units 2 hours before surgery and every 8 hours postoperatively (regimen I)
Trial: 2179782
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin 5000 units every 8 hours preoperatively (between two and nine doses) and every 8 hours postoperatively (regimen II)
Trial: 25978109
Drug: H2-rich water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-rich water (0.9 L/day) for 10 weeks
Trial: 21876446
Drug: dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose reduction
Trial: 17076823
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg cortisol
Trial: 17605632
Drug: Zoledronate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (4 mg, i.v.)
Trial: 17605632
Drug: Pamidronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (30 mg, i.v., for 2 consecutive days every 3 mo; n = 60)
Trial: 17605632
Drug: Neridronate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate (100 mg, i.v., for 2 consecutive days)
Trial: 12391349
Drug: Eletriptan 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eletriptan 80 mg vs Sumatriptan 50 mg
Trial: 12391349
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of eletriptan vs Sumatriptan
Trial: 12391349
Drug: Eletriptan 40
RxNorm normalized name: eletriptan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eletriptan 40 mg vs both Sumatriptan doses
Trial: 10437990
Drug: Higher-dose methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose methadone (mean dose 211 mg/d, range 110‐780 mg/d)
Trial: 10437990
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mean dose 65 mg/d)
Trial: 6986243
Drug: Intravenous cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cimetidine with antacid therapy
Trial: 6986243
Drug: Oral cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cimetidine with antacids
Trial: 29480853
Drug: Remote ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischemic preconditioning (RIPC) - induced by 4 times of 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper arm, followed by 5-min intervals of reperfusion at 1 hour before PCI therapy.
Trial: 27172434
Drug: Transdermal T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal T gel (1.25 g, 2.5 g, 5.0 g, 10 g, or 15 g daily) plus acyline injections every 2 weeks
Trial: 27172434
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections and transdermal gel
Trial: 25209519
Drug: Ozenoxacin 1%
RxNorm normalized name: OZENOXACIN 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozenoxacin 1% ointment (single doses)
Trial: 25209519
Drug: Ozenoxacin 1%
RxNorm normalized name: OZENOXACIN 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozenoxacin 1% ointment (multiple doses)
Trial: 25209519
Drug: Ozenoxacin 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozenoxacin 2% cream (multiple doses)
Trial: 25209519
Drug: Ozenoxacin 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozenoxacin 2% cream (multiple doses on intact and abraded skin)
Trial: 23000583
Drug: LAB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAB group (LAB‐G)
Trial: 23000583
Drug: LAB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAB with lactose group (L‐LAB‐G)
Trial: 23000583
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C‐G)
Trial: 18156660
Drug: Whey-protein supplement
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey-protein supplement (120 kcal, 30 g protein)
Trial: 15726879
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg oral dose)
Trial: 7805119
Drug: Consupren (Czech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consupren (Czech preparation of cyclosporin A)
Trial: 19014072
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for OSA
Trial: 10885237
Drug: Drip-infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drip-infusion of Diprivan (1% propofol emulsion)
Trial: 10885237
Drug: Syringe-pump administration
RxNorm normalized name: Japanese encephalitis virus vaccine, inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringe-pump administration of Diprivan (1% propofol emulsion)
Trial: 8316057
Drug: Garlic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic supplementation (600 mg/d of garlic powder for two weeks)
Trial: 27903994
Drug: Synbiotic supplement,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic supplement, 1000 mg/d for 6 weeks
Trial: 27903994
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules a day) for 6 weeks
Trial: 19068205
Drug: Beta-blocker bisoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker bisoprolol (n=55)
Trial: 19068205
Drug: Routine drugs
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drugs (ACE Inhibitors, diuretics, vasodilator drugs) (n=55)
Trial: 16897997
Drug: S-1 (2-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (2-week administration followed by 1-week rest)
Trial: 16897997
Drug: UFT (4-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (4-week administration followed by 2-week rest)
Trial: 9663830
Drug: Single-dose misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose misoprostol (400 microg)
Trial: 3947108
Drug: CQ PSK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQ PSK in alternate doses (Group B)
Trial: 3947108
Drug: CQ +
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CQ + PSK in alternate doses (Group D)
Trial: 19909829
Drug: IV ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ibandronate injections (2 mg every 2 months, 3 mg every 3 months)
Trial: 19909829
Drug: IV ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ibandronate (3 mg)
Trial: 19909829
Drug: Oral or
RxNorm normalized name: Doral Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or IV placebo